U.S. Markets open in 50 mins

Free Post Earnings Research Report: Perrigo Co.'s Quarterly Earnings Increased 3.23%

LONDON, UK / ACCESSWIRE / April 13, 2018 / Active-Investors.com has just released a free earnings report on Perrigo Co. PLC (NYSE: PRGO). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=PRGO. On March 01, 2018, Perrigo reported financial results for the fourth quarter and full year ended December 31, 2017. The Company surpassed analysts' estimates for revenue as well as earnings for Q4 FY17. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Perrigo most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Earnings Highlights and Summary

Perrigo's total revenues for Q4 FY17 reached $1.28 billion, a decrease of 3.61% from $1.33 billion in Q4 FY16 owing to divestitures. Excluding the impact of divestitures, sales increased 2.1% due to positive execution across all business segments. The reported revenue number exceeded analysts' consensus estimates of $1.25 billion.

Perrigo had a gross profit of $512.7 million in Q4 FY17 compared to $487.7 million in Q4 FY16, reflecting an increase of 5.12%. The Company's research and development (R&D) expenses surged 12.74% to $46.9 million y-o-y and distribution, selling, general, and administrative expenses declined 4.47% to $301.3 million y-o-y in the reported quarter. Perrigo had an operating profit of $158.5 million in Q4 FY17 compared to an operating loss of $484.6 million in Q4 FY16.

During Q4 FY17, Perrigo reported a net income of $73.1 million, after a net loss of $1.36 billion in Q4 FY16. The Company had diluted earnings per share (DEPS) of $0.52 in the reported quarter compared to a diluted loss per share of $9.48 in the previous-year quarter. The reported quarter results included amortization of intangible assets, restructuring charges, acquisition charges, and milestone revenue related to royalty rights. Perrigo's adjusted DEPS, excluding non-recurring items, was $1.28 in Q4 FY17, up 3.23% from $1.24 in Q4 FY16. The Company's adjusted DEPS for Q4 FY17 beat analysts' consensus estimates of $1.24 per share.

For the year ending December 31, 2017, Perrigo's total revenues were $4.95 billion, 6.33% lower than $5.28 billion in FY16. The Company had an operating profit of $598.2 million in the reported year compared to an operating loss of $2 billion in the previous year. Perrigo reported a net income of $119.6 million, or $0.84 per share in FY17, after a net loss of $4.01 billion, or $28.01 per share in FY16. The Company's adjusted DEPS for full year 2017, excluding non-recurring items, was $4.93; a decrease of 2.76% from $5.07 in FY16.

Perrigo Co.'s Segment Details

During Q4 2017, the Consumer Healthcare Americas (CHCA) segment's net revenues were $643.5 million, up 2.66% y-o-y; led by strong performance from the gastrointestinal and analgesics categories. This segment had an adjusted operating income of $148.8 million in Q4 FY17, an increase of 6.74% from $139.4 million in Q4 FY16.

For Q4 FY17, the Consumer Healthcare International (CHCI) segment's net revenues declined 10.82% to $374.1 million on a y-o-y basis. This segment's net sales grew 3.3% y-o-y on a constant currency basis in Q4 FY17, excluding exited European distribution businesses. CHCI segment's adjusted operating income for the quarter under review was $57.3 million, 57.42% higher than $36.4 million in the year ago corresponding quarter.

The Prescription Pharmaceuticals segment reported net revenues of $261.30 million in Q4 FY17, a decrease of 1.73% from the previous year's same quarter, owing to lower sales of Entocort due to competitive pressures and price erosion. The segment had an adjusted operating income of $99.5 million in Q4 FY18, 13.48% lower than $115 million in Q4 FY16.

Cash Matters

Perrigo had cash and cash equivalents of $678.7 million as on December 31, 2017, up 9.06% from $622.30 million as on December 31, 2016. The Company's long-term debt reduced 37.39% to $3.27 billion as on December 31, 2017, from $5.22 billion as on December 31, 2016.

Perrigo's cash flow from operating activities for FY17 was $698.9 million, 6.72% higher than the $654.90 million reported in FY16. The Company spent $88.6 million on additions to property, plant, and equipment in the reported year compared to $106.2 million in the previous year.

Perrigo distributed cash dividends of $91.1 million in FY17, an increase of 9.50% from $83.2 million in FY16. The Company spent $191.5 million on repurchase of ordinary shares in FY17.


For fiscal year 2018, Perrigo expects reported net sales to be in the range of $5.0 billion to $5.1 billion, reported operating income to be in the range of $682 million to $742 million, and reported DEPS to be in the range of $2.24 to $2.64. The Company expects adjusted operating income to be in the range of $1.03 billion and $1.09 billion, and adjusted DEPS to be in the range of $5.05 to $5.45 in FY18.

Stock Performance Snapshot

April 12, 2018 - At Thursday's closing bell, Perrigo's stock dropped 1.32%, ending the trading session at $80.86.

Volume traded for the day: 1.16 million shares, which was above the 3-month average volume of 1.04 million shares.

Stock performance in the past twelve-month period - up 17.17%

After yesterday's close, Perrigo's market cap was at $11.63 billion.

Price to Earnings (P/E) ratio was at 85.12.

The stock has a dividend yield of 0.94%.

The stock is part of the Healthcare sector, categorized under the Drug Related Products industry. This sector was up 0.8% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the ''Author'') and is fact checked and reviewed by a third-party research service company (the ''Reviewer'') represented by a credentialed financial analyst. For further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the ''Sponsor''), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors